Core Insights - Zacks Premium offers various tools to help investors make informed decisions in the stock market, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - The Zacks Style Scores are indicators designed to assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum [3] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales to find attractive investment opportunities [4] Growth Score - The Growth Style Score emphasizes a company's financial health and future potential, analyzing projected and historical earnings, sales, and cash flow to identify stocks with sustainable growth [5] Momentum Score - The Momentum Style Score helps investors capitalize on price trends by evaluating recent price changes and earnings estimate revisions, indicating favorable buying opportunities for high-momentum stocks [6] VGM Score - The VGM Score combines the three Style Scores to identify stocks with the best value, growth prospects, and momentum, serving as a strong indicator when used alongside the Zacks Rank [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors, with 1 (Strong Buy) stocks achieving an average annual return of +23.86% since 1988, significantly outperforming the S&P 500 [8] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down their choices [9] - For optimal returns, stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B are recommended, while 3 (Hold) stocks should also have A or B scores for potential upside [10] - The direction of earnings estimate revisions is crucial; stocks with lower ranks but high Style Scores may still face price declines due to negative earnings forecasts [11] Company Spotlight: AbbVie (ABBV) - AbbVie, based in North Chicago, IL, has strengthened its position in the pharmaceutical industry through the acquisition of Allergan for $63 billion, diversifying its portfolio beyond Humira [12] - AbbVie holds a 3 (Hold) Zacks Rank and a VGM Score of B, with a Growth Style Score of B indicating a projected year-over-year earnings growth of 44.9% for the current fiscal year [13] - Recent upward revisions from analysts for AbbVie's earnings estimates and an average earnings surprise of +3.2% further enhance its attractiveness to investors [13][14]

Company Overview - Moelis & Company is a global investment bank headquartered in New York, providing strategic and financial advisory services across various sectors, including mergers and acquisitions, capital market activities, restructurings, and corporate finance transactions involving public and private debt and equity [11]. Investment Ratings - Moelis & Company currently holds a Zacks Rank of 3 (Hold) with a VGM Score of A, indicating a solid position in the market [12]. - The company is considered a potential top pick for growth investors, with a Growth Style Score of B, forecasting a year-over-year earnings growth of 15.7% for the current fiscal year [12]. Earnings Estimates - In the last 60 days, five analysts have revised their earnings estimates higher for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.13 to $3.46 per share [12]. - Moelis & Company has demonstrated an average earnings surprise of +36.5%, reflecting its ability to exceed earnings expectations [12]. Investment Considerations - With a solid Zacks Rank and strong Growth and VGM Style Scores, Moelis & Company is recommended to be on investors' short lists for potential investment opportunities [13].

Company Overview - Vale S.A. is one of the world's largest mining companies with a market capitalization of approximately $61 billion, producing iron ore, iron ore pellets, copper, nickel, and also involved in manganese, ferroalloys, gold, silver, and cobalt [11]. Investment Potential - Vale S.A. is rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid investment potential [11]. - The company is considered a top pick for growth investors, with a Growth Style Score of B, forecasting year-over-year earnings growth of 16.5% for the current fiscal year [12]. - Recent upward revisions in earnings estimates by two analysts in the last 60 days have led to an increase in the Zacks Consensus Estimate by $0.10 to $2.12 per share [12]. - Vale S.A. has an average earnings surprise of +7.5%, further enhancing its attractiveness to investors [12].

Company Performance - Oil States International (OIS) has gained approximately 99.7% year-to-date, significantly outperforming the Oils-Energy sector, which has returned an average of 19.3% [4] - OIS currently holds a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for OIS' full-year earnings has increased by 1% over the past quarter, reflecting improved analyst sentiment [4] Industry Comparison - OIS is part of the Oil and Gas - Mechanical and Equipment industry, which has seen a year-to-date gain of about 28.9%, indicating that OIS is performing better than its industry peers [6] - In contrast, another Oils-Energy stock, Sasol (SSL), has returned 34.7% year-to-date and belongs to the Oil and Gas - Integrated - International industry, which is ranked 140 and has increased by 20.6% this year [5][7] Sector Ranking - The Oils-Energy group, which includes 234 companies, ranks 15 in the Zacks Sector Rank, which evaluates 16 different sector groups [2] - The Zacks Rank system is designed to identify stocks that may outperform the broader market over the next one to three months [3]

Core Viewpoint - H&R Block (HRB) has experienced a significant decline of 28.7% in its stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - HRB's current RSI reading is 27.01, indicating that the heavy selling pressure may be exhausting itself, which could lead to a reversal in the stock's trend [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts regarding HRB, with earnings estimates for the current year being raised by 0.5% over the last 30 days, which typically correlates with price appreciation [7]. - HRB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].

Core Viewpoint - Dillard's reported quarterly earnings of $10.08 per share, exceeding the Zacks Consensus Estimate of $9.98, but down from $13.48 per share a year ago, indicating a mixed performance despite beating earnings expectations [1] Financial Performance - The company achieved revenues of $1.96 billion for the quarter, which fell short of the Zacks Consensus Estimate by 2.85% and decreased from $2.02 billion year-over-year [2] - Over the last four quarters, Dillard's has surpassed consensus EPS estimates four times and topped revenue estimates twice [2] Stock Performance - Dillard's shares have increased by approximately 6.6% since the beginning of the year, contrasting with a slight decline of 0.1% in the S&P 500 [3] Future Outlook - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $9.22 for the upcoming quarter and $30.86 for the current fiscal year [4][7] - The Zacks Rank for Dillard's is currently 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] Industry Context - The Retail - Regional Department Stores industry, to which Dillard's belongs, is currently ranked in the top 7% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Insights - BrightSpring Health Services, Inc. (BTSG) is set to release its fourth-quarter 2025 results on February 27, with expectations of revenue at $3.35 billion and earnings at 34 cents per share. The company has previously exceeded earnings estimates by 11.11% in the last quarter and has a trailing four-quarter average earnings surprise of 45.05% [1][2]. Group 1: Q4 Performance Expectations - The fourth-quarter results are anticipated to reflect strong pharmacy momentum, steady provider growth, and improved balance sheet flexibility, with management indicating strong operational traction as of September [3]. - The Pharmacy Solutions segment is expected to be the primary growth driver, supported by robust growth in specialty scripts, increased generic utilization, and new limited distribution drug launches [4]. - The Infusion business is projected to contribute significantly, benefiting from robust volume growth and operational improvements, with potential upside from expansion into acute therapies and geographic scaling [5]. Group 2: Segment Performance - Sales in the Home & Community Pharmacy business are likely to be weak due to a delayed flu season and customer divestitures, although profitability may remain resilient due to an improved customer mix and automation initiatives [6]. - The Provider Services segment is expected to show strong performance across Home Health, Hospice, Rehab, and Personal Care businesses, driven by census expansion, quality scores, and Medicare Advantage contract momentum [7]. Group 3: Margin and Financial Metrics - BTSG reported a 30 basis point sequential improvement in gross margin in the third quarter, attributed to pharmacy mix improvement, operational efficiencies, and disciplined cost management, a trend likely to continue in the upcoming quarter [8]. - The company is expected to achieve its highest margin in the fourth quarter, aided by mix gains, cost control, and seasonal strength [11].

Core Viewpoint - Cheniere Energy, Inc. is expected to report its fourth-quarter 2025 results on February 26, with earnings estimated at $3.83 per share and revenues projected at $5.17 billion [1]. Group 1: Previous Quarter Performance - In the last reported quarter, Cheniere Energy achieved adjusted earnings per share of $4.75, surpassing the Zacks Consensus Estimate of $2.56, while revenues of $4.4 billion fell short of the estimate of $4.7 billion [2]. - The company has beaten earnings estimates in three of the last four quarters, with an average surprise of 79.95% [3]. Group 2: Upcoming Quarter Expectations - The Zacks Consensus Estimate for fourth-quarter 2025 earnings indicates an 11.55% year-over-year decrease, while revenues are expected to increase by 16.66% compared to the previous year [3]. - Cheniere Energy's revenue growth is anticipated due to strong LNG sales, with a projected increase of 16.4% from the year-ago quarter [5]. Group 3: Factors Influencing Performance - The company primarily generates revenue through long-term, take-or-pay contracts, which provide stable cash flows, and also benefits from purchasing natural gas, converting it to LNG, and selling it in global markets [4]. - Robust demand for LNG from Asia and Europe is expected to support higher shipment volumes, with long-term contracts covering over 80% of volumes stabilizing cash flows despite market volatility [6]. - Rising expenses, which were 24% higher in the third quarter compared to the previous year, are likely to continue impacting margins negatively due to inflationary pressures [7]. Group 4: Earnings Prediction - Cheniere Energy has a 0.48% Earnings ESP, indicating a potential earnings beat, and currently holds a Zacks Rank of 3 [9][11]. - The company's model suggests a favorable outlook for earnings performance in the upcoming report [10].

Core Viewpoint - Sempra Energy (SRE) is expected to report its fourth-quarter 2025 results on February 26, with an anticipated earnings decrease of 24.7% year-over-year, despite factors supporting regulated earnings and top-line performance [1][5][9]. Factors Impacting Q4 Results - The introduction of new interim rates and continued strong rate-based growth are likely to have positively influenced Sempra Energy's regulated earnings and overall performance [2][9]. - Continued investments in infrastructure, including grid modernization and clean energy projects, are expected to enhance system reliability and operational efficiency [3]. - Sustained customer growth across service territories is anticipated to have increased electricity and natural gas volumes, contributing to financial performance [3]. Weather and Economic Influences - Varied temperature trends during the October-December period, with most regions experiencing above-normal temperatures, likely reduced electricity demand for heating, potentially impacting top-line performance negatively [4]. - Higher operating expenses and increased interest expenses may have offset some of the positive factors in the upcoming quarter [4][9]. Earnings Expectations - The Zacks Consensus Estimate for earnings is set at $1.13 per share, reflecting a year-over-year decrease of 24.7% [5]. - Revenue estimates are pegged at $3.64 billion, indicating a 3.1% decline year-over-year [5]. Earnings Prediction Model - The earnings prediction model suggests a potential earnings beat for Sempra Energy, supported by a positive Earnings ESP of +4.73% and a Zacks Rank of 3 (Hold) [6][7].

Core Insights - Diversified Healthcare (DHC) reported quarterly funds from operations (FFO) of $0.09 per share, missing the Zacks Consensus Estimate of $0.12 per share, but showing an improvement from $0.02 per share a year ago [1] - The company experienced an FFO surprise of -25.00% for the quarter, and has only surpassed consensus FFO estimates once in the last four quarters [2] - Revenues for the quarter were $379.57 million, which was 4.53% below the Zacks Consensus Estimate, and slightly down from $379.62 million year-over-year [3] Financial Performance - The FFO for the last quarter was $0.09 per share, compared to an expected $0.12 per share, indicating a significant miss [1] - The company’s revenues of $379.57 million fell short of expectations, marking a slight decline from the previous year's revenues [3] - Over the last four quarters, the company has exceeded revenue estimates twice, indicating some variability in performance [3] Market Position and Outlook - Diversified Healthcare shares have increased by approximately 28.7% since the beginning of the year, outperforming the S&P 500, which gained only 0.9% [4] - The future performance of the stock will largely depend on management's commentary during the earnings call and the outlook for FFO [4][5] - The current consensus FFO estimate for the upcoming quarter is $0.14, with projected revenues of $395.44 million, and for the current fiscal year, the estimate is $0.57 on $1.61 billion in revenues [8] Industry Context - The REIT and Equity Trust - Other industry, to which Diversified Healthcare belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, which may impact stock performance [9] - Empirical research indicates a strong correlation between stock movements and estimate revisions, suggesting that investors should monitor these trends closely [6][7]